[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"breast-cancer-screening\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:breast-cancer-screening":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,41,66,97,123,153,176,201,229,257,279,304,333,355,374],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100644821","instagram-and-podcast-intervention-for-breast-cancer-awareness-and-screening-100644821",false,"NCT07673588","Instagram and Podcast Intervention for Breast Cancer Awareness and Screening","The Effect of an Instagram- and Podcast-Based Intervention on Women's Breast Cancer Awareness, Health Beliefs, and Screening Behaviors: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Women aged 20-39 years\n* Able to read and write Turkish\n* Turkish citizens\n* Have an active Instagram account and access it at least once daily\n* No previous diagnosis of cancer\n* Willing to participate and provide informed consent\n\nExclusion Criteria:\n\n* No access to a smartphone with the Instagram application\n* Visual, hearing, or cognitive impairment that may prevent participation in the intervention\n\nWithdrawal Criteria:\n\n* Failure to complete the assigned podcast sessions during the intervention period\n* Participant request to withdraw from the study at any time",true,"FEMALE","20 Years","39 Years",{"count":21,"type":22},180,"ESTIMATED","INTERVENTIONAL",[25],"NA","Breast cancer is the most common cancer among women worldwide. This randomized controlled trial aims to evaluate the effect of an Instagram- and podcast-based intervention on women's breast cancer awareness, health beliefs, and breast cancer screening behaviors among women aged 20-39 years.",[28,29],"Breast Cancer","Breast Cancer Screening","NOT_YET_RECRUITING","2026-07-01",{"date":33,"type":34},"2026-07-02","ACTUAL",{"date":31,"type":22},{"date":37,"type":22},"2026-12-01",{"name":39,"class":40},"Ankara University","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":16,"sex":47,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":23,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":4},"100640657","community-gateway-to-health-study-100640657","NCT07592793","Community Gateway to Health Study","Study participants include community health center and community partner staff participating in surveys and interviews about the implementation of the intervention.\n\nInclusion Criteria:\n\n* Community health center staff or community partners\n* Age 18 or older\n\nExclusion Criteria:\n\n* Under 18\n\nPatients will not be individually recruited for the study because the intervention is being offered as part of routine care.","ALL","18 Years",{"count":50,"type":22},100,[25],"The goal of this study is to evaluate the impact of a multi-level intervention on cancer prevention and social determinants of health outcomes. This partnership between academic and community-based researchers aims to link community health centers and communities in ways that maximize both civic engagement and participation in cancer control care. The system-level intervention consists of two components: (1) provision of community health center systems-level tools for cancer screening (breast, cervical, colorectal) and tobacco cessation treatment gaps; and (2) digital access screening and navigation. These interventions will be delivered via usual care.",[29,54,55,56],"Cervical Cancer Screening","Colon Cancer Screening","Tobacco Cessation","2026-05-11",{"date":59,"type":34},"2026-05-18",{"date":61,"type":22},"2026-06",{"date":63,"type":22},"2029-07",{"name":65,"class":40},"Harvard School of Public Health (HSPH)",{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":16,"sex":17,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":4,"studyType":23,"phases":76,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":92,"leadSponsor":94,"locationsCount":96},"100610470","bundled-cancer-screening-and-genetic-services-navigation-100610470","NCT07228000","Bundled Cancer Screening and Genetic Services Navigation","Inclusion Criteria:\n\n1. Seeking screening navigation services through programs at a participating site (Georgetown Lombardi Cancer Center or Helen F. Graham Cancer Center \\& Research Institutes)\n2. Eligible for breast cancer screening while also due and eligible for colorectal cancer screening (per USPSTF guidelines)\n3. Female sex\n4. Aged 45-74\n5. Identify as Black\u002FAfrican American race and\u002For Hispanic\u002FLatin(e)(a) ethnicity\n6. Speak English or Spanish with enough fluency to complete study activities\n7. Stated willingness to comply with all study procedures (navigation, surveys) and availability for the duration of the study\n8. Provision of completed electronic informed consent form\n\nExclusion Criteria:\n\n1. Not engaged with or planning to use navigation programs at Georgetown Lombardi Cancer Center and Helen F. Graham Cancer Center \\& Research Institute\n2. Not eligible for breast cancer screening or not due and eligible for colorectal cancer screening (per USPSTF guidelines)\n3. History of breast and\u002For colorectal cancer; or Reporting symptoms related to breast and\u002For colorectal cancer (e.g., GI bleeding, breast mass)\n4. Male sex, Intersex, or other sex\n5. Under age 45 or over age 74\n6. Identifies as neither Black\u002FAfrican American race nor Hispanic\u002FLatin(e)(a) ethnicity\n7. Speaks neither English nor Spanish with enough fluency to complete study activities\n8. Stated unwillingness to comply with study procedures (navigation, surveys) or unavailability for the duration of the study\n9. Inability to provide electronic informed consent, or needing another person to authorize informed consent on their behalf","45 Years","74 Years",{"count":75,"type":22},820,[25],"The goal of this study is to test bundled familial cancer risk assessment + multicancer (colorectal + breast) vs. single (breast) cancer navigation, using a wait list control for colorectal cancer screening referral and navigation. Among those eligible, this study will test usual care referral to genetic services vs. pretest education + usual care referral. The study also will assess how bundled multicancer navigation works and for whom it is most effective through a multisite, mixed-methods patient- and organization-level process evaluation.",[29,55,79],"Genetics Predisposition",[81,82,83,84,85,86],"navigation","mammography","colonoscopy","Fecal Immunochemical Test","genetic testing","risk assessment","RECRUITING","2026-05-06",{"date":90,"type":34},"2026-05-08",{"date":88,"type":34},{"date":93,"type":22},"2029-05-31",{"name":95,"class":40},"Georgetown University",2,{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":16,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":105,"phases":4,"briefSummary":106,"conditions":107,"keywords":108,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":122},"100598153","bbrilliant-revelation-comparision-study-100598153","NCT07067788","B.Brilliant Revelation Comparision Study","A Clinical Comparison of Siemens Mammomat B.Brilliant , A Novel Wide-Angel Digitial Breast Tomosynthesis System With Siemens Mammomat Revelation , A Standard Wide-Angle Digital Breast Tomosynthesis System","Inclusion Criteria\n\n1. Participants will be ≥ 18 years of age.\n2. Participants will be females (sex assigned at birth).\n3. Participants will be presenting for clinical diagnostic mammography with suspicious calcifications or calcifications associated with other lesion types\n4. Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.\n\nExclusion Criteria\n\n1. Females who are breast-feeding will not be eligible for this study\n2. Pregnant women will not be included. All females of childbearing potential must attest that they are not pregnant.\n3. Inability to tolerate imaging procedures in the opinion of an investigator or treating physician.\n4. Any current medical condition, illness, or disorder, as assessed by medical record review and\u002For self-reported, that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study.",{"count":50,"type":22},"OBSERVATIONAL","This is an observational study to evaluate the MAMMOMAT B.brilliant system. All diagnostic decisions are made by the treating radiologist based upon standard of care clinical imaging acquired on FDA approved devices",[29],[109,110,111,112],"breast","mammogram","breast cancer","female","2026-04-23",{"date":115,"type":34},"2026-04-24",{"date":117,"type":34},"2025-12-15",{"date":119,"type":22},"2027-01-30",{"name":121,"class":40},"University of Pennsylvania",1,{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":16,"sex":17,"minAge":130,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":23,"phases":134,"briefSummary":135,"conditions":136,"keywords":139,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":122},"100588307","social-media-based-education-on-cancer-screening-awareness-in-women-a-randomized-controlled-trial-100588307","NCT06939699","Social Media-Based Education on Cancer Screening Awareness in Women: A Randomized Controlled Trial","The Effect of Social Media-Based Education on Women's Knowledge, Attitudes, and Health Literacy Regarding Cancer Screenings: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Female participants aged 30 to 70 years\n* Use Instagram and\u002For WhatsApp actively\n* Literate and able to complete online forms\n* Voluntarily consent to participate\n\nExclusion Criteria:\n\n* Diagnosed with any type of cancer\n* Have undergone previous cancer screening","30 Years","70 Years",{"count":133,"type":22},132,[25],"This randomized controlled trial investigates the impact of a social media-based educational program on women's knowledge, attitudes, and digital health literacy regarding breast, cervical, and colorectal cancer screenings. The intervention is based on the Socio-Ecological Model and aims to improve awareness and screening participation. Participants in the intervention group receive daily educational content for 8 weeks via social media platforms (WhatsApp\u002FInstagram), while the control group receives two standard online education sessions via Microsoft Teams app. The study includes 132 women aged 30 to 70 in Türkiye who have not previously participated in cancer screenings. The primary outcomes include changes in cancer knowledge, attitudes, and digital health literacy levels measured by validated scales.",[54,29,137,138],"Colorectal Cancer Screening","Digital Health Literacy",[140,141,142,143,144],"internet based intervention","cancer screening","social media","health literacy","education","2026-04-22",{"date":113,"type":34},{"date":148,"type":22},"2026-07-15",{"date":150,"type":22},"2026-08-20",{"name":152,"class":40},"Emine Ergin",{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":16,"sex":47,"minAge":48,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":105,"phases":4,"briefSummary":161,"conditions":162,"keywords":166,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":122},"100621759","signature-development-and-validation-protocol-for-an-epigenetic-assay-in-diagnosing-breast-cancer-100621759","NCT07374796","Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Breast Cancer","Inclusion Criteria:\n\n* 18 years old or older\n* Patient of UMMS\n* Willing and able to consent to study procedures listed in the protocol\n* Ability to speak and understand English\n\nExclusion Criteria:\n\n* Younger than 18 years old\n* Patient not cared for at UMMS\n* Unable to consent to study procedures listed in the protocol\n* Unable to speak or understand English",{"count":160,"type":22},450,"The purpose of this research study is to test a new process for diagnosing breast cancer by examining changes to your DNA that can be detected from a blood test. The information we learn by doing this study could potentially help people in the future.\n\nParticipants in this study will have blood samples collected, have their medical records reviewed by study personnel and fill out questionnaires at different time points during the study. Blood sample collection will occur during normal routine clinic visits. Participation in this study will last approximately 5 years.",[163,164,165,29],"Breast Cancer (Locally Advanced or Metastatic)","Healthy Volunteers (HV)","Unhealthy Volunteers",[28,29,167,165],"Healthy Volunteers","2026-04-21",{"date":145,"type":34},{"date":171,"type":22},"2026-06-01",{"date":173,"type":22},"2032-07",{"name":175,"class":40},"University of Maryland, Baltimore",{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":47,"minAge":48,"maxAge":4,"enrollmentInfo":183,"targetDuration":4,"studyType":23,"phases":185,"briefSummary":186,"conditions":187,"keywords":189,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":197,"completionDateStruct":198,"leadSponsor":199,"locationsCount":4},"100634547","cancer-awareness-among-syrian-migrants-100634547","NCT07541105","Cancer Awareness Among Syrian Migrants","A Theory-Driven Educational Intervention to Enhance Cancer Screening Uptake Among Syrian Migrants in Turkey: A Study Protocol","Inclusion Criteria:\n\n* over 18 years of age\n* hold Syrian citizenship\n* be registered with the Migrant Health Center in Mersin province\n* have proficiency in Turkish or Arabic\n* voluntarily agree to participate\n\nExclusion Criteria:\n\n* if they hold Turkish citizenship\n* have a diagnosed psychiatric disorder\n* have been diagnosed with cancer\n* wish to withdraw from the study",{"count":184,"type":22},30,[25],"This study aims to develop and evaluate a theory-based educational intervention to improve cancer screening participation among Syrian migrants in Turkey. The study will also develop a Cancer Protection Motivation Scale (CPMS) to measure individuals' motivation toward cancer screening. Using a mixed-methods design, the study will explore barriers, beliefs, and behaviors related to breast, cervical, and colorectal cancer screening. The effectiveness of the intervention will be assessed using a pretest-posttest design. The findings are expected to support culturally appropriate strategies to improve cancer screening uptake among migrant populations.",[29,54,137,188],"Cancer Prevention Behavior",[190,191,192,193,194],"Breast cancer","Colon cancer","Cervical cancer","Protection motivation","Reduced inequalities","2026-04-20",{"date":115,"type":34},{"date":195,"type":22},{"date":148,"type":22},{"name":200,"class":40},"Toros University",{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":207,"eligibilityCriteria":208,"healthyVolunteers":16,"sex":17,"minAge":72,"maxAge":209,"enrollmentInfo":210,"targetDuration":4,"studyType":23,"phases":212,"briefSummary":213,"conditions":214,"keywords":217,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":122},"100598760","screening-mammography-single-reading-by-one-radiologist-with-ai-vs-double-reading-by-two-radiologists-ai-bcsq-100598760","NCT07075679","Screening Mammography: Single Reading by One Radiologist With AI vs. Double Reading by Two Radiologists (AI-BCSQ)","Use of Artificial Intelligence in Breast Cancer Screening: Impact of AI-Assisted Single Reading by One Radiologist on Screening Quality Indicators Compared to Standard Double Reading by Two Radiologists Without AI","AI-BCSQ","Inclusion Criteria:\n\n* age 45-69, asymptomatic woman participating in breast cancer screening programme\n\nExclusion Criteria:\n\n* clinical signs of breast disease - indication for diagnostic mammography","69 Years",{"count":211,"type":22},8000,[25],"A randomized prospective study comparing the evaluation of mammography images in a breast cancer screening programme by a single radiologist with AI support versus standard double reading by two radiologists without AI support.",[29,215,216],"Artificial Intelligence (AI)","Breast Cancer Screening and Diagnosis",[111,218,219],"screening","artificial intelligence","2026-04-01",{"date":222,"type":34},"2026-04-02",{"date":224,"type":34},"2025-10-06",{"date":226,"type":22},"2028-10-05",{"name":228,"class":40},"University Hospital Olomouc",{"id":230,"slug":231,"hasResults":11,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":235,"eligibilityCriteria":236,"healthyVolunteers":11,"sex":17,"minAge":72,"maxAge":237,"enrollmentInfo":238,"targetDuration":4,"studyType":105,"phases":4,"briefSummary":240,"conditions":241,"keywords":242,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":122},"100624889","breast-density-impact-on-mammographic-screening-for-breast-cancer-diagnosis-100624889","NCT07415499","Breast Density Impact on Mammographic Screening for Breast Cancer Diagnosis","Retrospective Study on Patients Undergoing Mammographic Screening to Evaluate the Impact of Breast Density on Breast Cancer Diagnosis","SINATRA","Inclusion Criteria:\n\n* Women aged 45 to 75 years who participated in the \"Prevenzione Serena\" mammography screening program and underwent screening mammography at ASL CN2 between September 25, 2023, and May 3, 2024.\n* Signed informed consent or equivalent substitute declaration, when applicable.\n\nExclusion Criteria:\n\n* Women with a history of mastectomy.\n* Women with breast implants.\n* Women with cardiac implantable devices, such as pacemakers or loop recorders.\n* Cases in which the Insight BD software cannot be applied due to compression thickness below 15 mm.","75 Years",{"count":239,"type":22},3300,"This retrospective, observational study aims to evaluate how breast density affects the accuracy and outcomes of mammographic screening for breast cancer within the regional screening program \"Prevenzione Serena\".\n\nBreast density is an important factor because dense breast tissue can make it more difficult to detect breast cancer on a mammogram. Dense tissue and tumors both appear white on a mammogram, which may hide abnormalities and lead to missed cancers or false-positive results.\n\nWomen aged 45 to 75 years who underwent routine mammographic screening at ASL CN2 between September 2023 and May 2024 will be included. Breast density will be classified using the BI-RADS system (categories A-D), and the study will assess whether women with dense breasts (categories C and D) experience higher rates of recalls for second-level examinations such as ultrasound, MRI, etc).\n\nThe study also includes an internal validation of Insight BD, an automated breast-density measurement software used at ASL CN2. The software will be evaluated using a mammography phantom (to verify technical accuracy) and by comparing its BI-RADS density classifications with readings from two radiologists (one expert and one less experienced). This will help determine whether the software can support radiologists, especially in evaluating dense breast tissue.\n\nAdditional factors such as menopausal status, family history of breast cancer, and hormone therapy will also be examined to understand how they relate to breast density and screening outcomes. The study aims to quantify the frequency of false-positive recalls-cases in which additional tests are recommended but cancer is not found-because these events can increase patient anxiety and healthcare workload.\n\nUltimately, this research seeks to provide evidence that may inform future screening guidelines and support more personalized approaches, particularly for women with dense breasts.",[29,216],[190,243,244,245,246,247],"Breast cancer screening","BRADS","Mammography","Dense breast","Breast imaging","2026-02-16",{"date":250,"type":34},"2026-02-17",{"date":252,"type":34},"2026-01-12",{"date":254,"type":22},"2026-09",{"name":256,"class":40},"Azienda Sanitaria Locale CN2 Alba-Bra",{"id":258,"slug":259,"hasResults":11,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":4,"eligibilityCriteria":263,"healthyVolunteers":16,"sex":17,"minAge":264,"maxAge":209,"enrollmentInfo":265,"targetDuration":4,"studyType":23,"phases":267,"briefSummary":268,"conditions":269,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":122},"100624577","ai-enhanced-imaging-in-population-breast-cancer-screening-100624577","NCT07411443","AI-Enhanced Imaging in Population Breast Cancer Screening","Population-based Breast Cancer Screening Study Using AI-Assisted Imaging Technology","Inclusion Criteria:\n\n* women aged 35 to 69 years, who were attending the \"Two Cancers (Breast and Cervical Cancer) Screening\" project, and had no history of breast cancer, including in-situ cancer, or any other cancers in the previous five years.\n\nExclusion Criteria:\n\n* have serious cardiopulmonary insufficiency, liver or kidney insufficiency, or other systemic diseases, and a life expectancy of less than five years","35 Years",{"count":266,"type":22},16000,[25],"Artificial Intelligence (AI)-assisted imaging technologies (including AI-assisted breast ultrasound and AI-assisted mammography) can effectively improve the accuracy and efficiency of breast imaging examinations, but their application in large-scale population-based breast cancer screening remains very limited.\n\nThis project aims to improve the effectiveness and feasibility of breast cancer screening by addressing the core issues and bottlenecks in population-based breast cancer screening. We will conduct a prospective cluster-controlled screening trial in the general population, with district-based cluster grouping. The intervention group will undergo combined screening using AI-assisted ultrasound plus AI-assisted mammography, while the control group will receive conventional screening: breast ultrasound for initial screening and mammography for secondary screening.\n\nBased on population screening practices, we will evaluate the effectiveness of AI-assisted imaging diagnostic technology in various technical aspects of actual screening and perform cost-effectiveness analyses. This study will investigate the application of AI-assisted breast imaging technology in population-based breast cancer screening, providing scientific evidence for the large-scale implementation of AI-assisted imaging technologies. Furthermore, by combining population screening practices with model simulations, we will explore multi-dimensional breast cancer screening strategies to optimize screening approaches and technologies for the Chinese population.",[29],"2026-02-11",{"date":272,"type":34},"2026-02-13",{"date":274,"type":34},"2025-01-01",{"date":276,"type":22},"2027-12-31",{"name":278,"class":40},"Fudan University",{"id":280,"slug":281,"hasResults":11,"nctId":282,"briefTitle":283,"officialTitle":284,"acronym":4,"eligibilityCriteria":285,"healthyVolunteers":16,"sex":47,"minAge":48,"maxAge":4,"enrollmentInfo":286,"targetDuration":4,"studyType":23,"phases":288,"briefSummary":290,"conditions":291,"keywords":292,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":295,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":301,"locationsCount":303},"100587888","phase-4-a-trial-comparing-screening-mammography-with-and-without-assistance-from-artificial-intelligence-for-breast-cancer-detection-and-recall-rates-in-adult-patients-100587888","NCT06934239","A Trial Comparing Screening Mammography With and Without Assistance From Artificial Intelligence for Breast Cancer Detection and Recall Rates in Adult Patients","A Randomized Controlled Trial Comparing Screening Mammography With and Without Assistance From Artificial Intelligence for Breast Cancer Detection and Recall Rates in Adult Patients","This trial will include all radiologists interpreting screening mammography and all adult patients undergoing screening mammography at any of the participating breast imaging facilities across 6 regional health systems (UCLA, UC San Diego, University of Washington-Seattle, University of Wisconsin-Madison, Boston Medical Center, and University of Miami) during the trial period. Individuals must meet the following eligiblity criteria.\n\nInclusion Criteria:\n\n1. Be at least 18 years of age or older\n2. Receive a screening mammogram at one of the participating breast imaging facilities OR be a radiologist who interprets screening mammograms at one of the participating breast imaging facilities.\n\nExclusion Criteria:\n\n1\\. Patients who have opted out of all research at the health system",{"count":287,"type":22},400000,[289],"PHASE4","The goal of this clinical trial is to compare patient-centered outcomes when screening digital breast tomosynthesis (DBT) exams are interpreted with versus without a leading FDA-cleared artificial intelligence (AI) decision-support tool in real-world U.S. settings and to assess patients' and radiologists' perspectives on AI in medicine.\n\nThe main question it aims to answer is: Does an FDA-cleared AI decision-support tool for digital tomosynthesis (DBT) improve screening outcomes in real world US clinical settings?\n\nThis trial will include all interpreting radiologists and all adult patients undergoing screening mammography at any of the participating breast imaging facilities across 6 regional health systems (University of California, Los Angeles (UCLA), University of California, San Diego (UCSD), University of Washington-Seattle, University of Wisconsin-Madison, Boston Medical Center, and University of Miami) during the trial period.\n\nAll screening mammograms at these facilities will be randomized to either intervention (radiologist assisted by an AI decision support tool) versus usual care (radiologist alone) to see if interpreting these mammograms with the AI tool's assistance improves patient screening outcomes.\n\nWe are targeting 400,000 screening exams across the participating health systems in this trial.",[29,215],[243,293],"Artificial intelligence (AI)","2025-11-24",{"date":296,"type":34},"2025-11-26",{"date":298,"type":34},"2025-10-15",{"date":300,"type":22},"2030-03-01",{"name":302,"class":40},"Jonsson Comprehensive Cancer Center",6,{"id":305,"slug":306,"hasResults":11,"nctId":307,"briefTitle":308,"officialTitle":309,"acronym":310,"eligibilityCriteria":311,"healthyVolunteers":16,"sex":17,"minAge":130,"maxAge":73,"enrollmentInfo":312,"targetDuration":4,"studyType":23,"phases":314,"briefSummary":315,"conditions":316,"keywords":318,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":324,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":330,"locationsCount":332},"100256720","women-informed-to-screen-depending-on-measures-of-risk-wisdom-study-100256720","NCT02620852","Women Informed to Screen Depending on Measures of Risk (Wisdom Study)","Enabling a Paradigm Shift: A Preference-Tolerant RCT of Personalized vs. Annual Screening for Breast Cancer (Wisdom Study)","WISDOM","Inclusion Criteria:\n\n1. Female\\*\n2. Age 30 years to 74 years old\\*\\*\n3. Reside in the United States\\*\\*\\*\n\nNOTE\\*: As of 2019, we are now enrolling all persons who identify as female, and will capture both their sex at birth and gender identity in the baseline survey.\n\nNOTE\\*\\*: Eligibility from 2016 - October 2023 included ages 40-74 (WISDOM 1.0) and expanded to age 30 in October 2023 (WISDOM 2.0).\n\nNOTE\\*\\*\\*: As of 2019, recruitment is available nationwide. Original eligibility was limited to California, North Dakota, South Dakota, Iowa, Minnesota, Alabama, Louisiana, Illinois OR have coverage from a participating health plan.\n\nExclusion Criteria:\n\n1. Prior Breast cancer or ductal carcinoma in situ (DCIS) diagnosis\n2. Prior prophylactic bilateral mastectomy\n3. Inability to provide consent\n4. Non-English or Spanish proficiency (Spanish participation available: June 2019)",{"count":313,"type":22},100000,[25],"Most physicians still use a one-size-fits-all approach to breast screening in which all women, regardless of their personal history, family history or genetics (except BRCA carriers) are recommended to have annual mammograms starting at age 40. Mammograms benefit women by detecting cancers early when they are easier to treat, but they are not perfect. Recent news stories have discussed some of the potential harms: large numbers of positive results that cause stressful recalls for additional mammograms and biopsies. With the current screening approach, half of the women who undergo annual screening for ten years will have at least one false positive biopsy. Potentially more important are cancer diagnoses for growths that might never come to clinical attention if left alone (called \"overdiagnosis\"). This can lead to unnecessary treatment. Even more concerning is evidence that up to 20% of breast cancers detected today may fall into the category of \"overdiagnosis.\"\n\nThe WISDOM 1.0 study compares annual screening with a risk-based breast cancer screening schedule, based upon each woman's personal risk of breast cancer. The investigators have designed the study to be inclusive of all, so that even women who might be nervous about being randomly assigned to receive a particular type of care (a procedure that is typical in clinical studies) will still be able to participate by choosing the type of care they receive.\n\nFor participants in the risk-based screening arm, each woman will receive a personal risk assessment that includes her family and medical history, breast density measurement and tests for genes (mutations and variations) linked to the development of breast cancer. Women who have the highest personal risk of developing breast cancer will receive more frequent screening, while women with a lower personal risk would receive less frequent screening. No woman will be screened less than is recommended by the USPSTF breast cancer screening guidelines.\n\nIf this study is successful, women will gain a realistic understanding of their personal risk of breast cancer as well as strategies to reduce their risk, and fewer women will suffer from the anxiety of false positive mammograms and unnecessary biopsies. The investigators believe this study has the potential to transform breast cancer screening in America.\n\nStarting in Spring 2023, WISDOM's design shifted to remove the randomized option, but will continue with the preference\u002Fself-selection option for participation (WISDOM 2.0). Participants will therefore continue to choose their study arm (Personalized or Annual) rather than have the option to be randomized. This study design change was made after review of the WISDOM 1.0 data by an independent monitoring committee, which indicates that personalized screening does not cause harm. WISDOM 2.0 has also lowered the eligibility to ages 30-74. Women ages 30-39 will only be offered to join the Personalized Arm.",[29,317,28],"Breast Carcinoma in Situ",[319,82,320,86,321,190,322],"Breast screening","prevention","DCIS","Wisdom","2025-11-19",{"date":325,"type":34},"2025-11-25",{"date":327,"type":34},"2016-08-31",{"date":329,"type":22},"2026-09-01",{"name":331,"class":40},"University of California, San Francisco",11,{"id":334,"slug":335,"hasResults":11,"nctId":336,"briefTitle":337,"officialTitle":337,"acronym":338,"eligibilityCriteria":339,"healthyVolunteers":16,"sex":17,"minAge":340,"maxAge":73,"enrollmentInfo":341,"targetDuration":4,"studyType":23,"phases":343,"briefSummary":344,"conditions":345,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":353,"locationsCount":96},"100503906","madre-mammograms-available-due-to-research-and-education-100503906","NCT05841355","MADRE (Mammograms Available Due to Research and Education)","MADRE","Aim 1\n\nInclusion Criteria:\n\n* female biological sex\n* identification as Latinas\n* non-adherence to USPSTF guidelines (42-74 years old, no mammogram in past 2 years, no previous BC diagnosis)\n* no previous history of health volunteerism\n* not a network member enrolled in Aim 2.\n\nExclusion Criteria\n\n\\* Not meeting at least one of the aforementioned Aim 1 inclusion criteria.\n\nAim 2.\n\nInclusion Criteria:\n\n* female biological sex\n* eligibility to obtain BC screenings by USPSTF guidelines (i.e., 40-74 years old, no personal BC history)\n* referral from Aim 1 participants\n* no previous history of health volunteerism\n* no participation in the RCT (not an Aim 1 participant, no Session #3 attendance).\n\nExclusion Criteria:\n\n* Not meeting at least one of the aforementioned Aim 1 inclusion criteria.","40 Years",{"count":342,"type":22},600,[25],"The design builds on past studies by integrating social network analysis (SNA) and implementation science (IS) into a longitudinal randomized clinical trial (RCT). The investigator will compare the long-term effects of interventions by examining guideline-concordant initial and repeat Breast Cancer (BC) screening.",[29],"2025-07-07",{"date":348,"type":34},"2025-07-10",{"date":350,"type":34},"2023-03-14",{"date":352,"type":22},"2027-08-31",{"name":354,"class":40},"University of Illinois at Chicago",{"id":356,"slug":357,"hasResults":11,"nctId":358,"briefTitle":359,"officialTitle":359,"acronym":4,"eligibilityCriteria":360,"healthyVolunteers":11,"sex":17,"minAge":130,"maxAge":237,"enrollmentInfo":361,"targetDuration":4,"studyType":105,"phases":4,"briefSummary":363,"conditions":364,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":366,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":372,"locationsCount":122},"100585482","establishment-and-clinical-application-of-breast-cancer-risk-prediction-model-based-on-traditional-chinese-medicine-four-diagnostic-instruments-and-ultrasound-100585482","NCT06902935","Establishment and Clinical Application of Breast Cancer Risk Prediction Model Based on Traditional Chinese Medicine Four Diagnostic Instruments and Ultrasound","Inclusion Criteria:\n\n1. Female patients aged between 30 and 75.\n2. Patients who have a mass detected by US examination, need to undergo surgery or needle biopsy, and obtain a definite pathological result.\n3. Patients who have obtained complete identification results of tongue, pulse, face, and constitution through the traditional Chinese medicine four diagnostic instruments.\n\nExclusion Criteria:\n\n\\- 1. Patients with severe heart, liver, or kidney insufficiency, or other serious systemic diseases.\n\n2\\. Patients with a history of other malignant tumors. 3. Cases with poor - quality B - ultrasound images. 4. Cases with an unclear pathological diagnosis. 5. Patients with obvious lesions on the face, in the oral cavity, or on the tongue that may affect the measurement results.",{"count":362,"type":22},1500,"Construct a breast cancer risk prediction model based on traditional Chinese medicine four diagnostic instruments and B-ultrasound images. Ensure that the key evaluation indicators of the model reach a high level through clinical verification, so as to contribute to accurate clinical diagnosis and treatment decision-making.",[29],"2025-03-24",{"date":367,"type":34},"2025-03-30",{"date":369,"type":22},"2025-04-26",{"date":371,"type":22},"2027-04-26",{"name":373,"class":40},"Taizhou Hospital",{"id":375,"slug":376,"hasResults":11,"nctId":377,"briefTitle":378,"officialTitle":378,"acronym":4,"eligibilityCriteria":379,"healthyVolunteers":11,"sex":47,"minAge":130,"maxAge":237,"enrollmentInfo":380,"targetDuration":4,"studyType":105,"phases":4,"briefSummary":382,"conditions":383,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":385,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":122},"100583460","application-of-cfdna-methylation-detection-in-auxiliary-diagnosis-of-breast-cancer-100583460","NCT06876610","Application of CfDNA Methylation Detection in Auxiliary Diagnosis of Breast Cancer","Inclusion Criteria for All the Participants:\n\n* With confirmed pathological diagnosis and molecular subtyping results\n* Ability to provide a written informed consent\n\nExclusion Criteria for Cancer Arm Participants:\n\n* Patients with a history of or currently suffering from other malignancies\n* Pregnant or planning to become pregnant female patients\n* Patients who have received cancer treatment, including surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy, before blood draw\n* Patients with a history of blood transfusion within the past month\n* Patients with a known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation\n* Patients with persistent fever or undergoing anti-inflammatory treatment within 14 days before blood draw\n* Any other conditions that the researcher deems may make the patient unsuitable for inclusion in the study or may interfere with the completion of the study\n* Patients in poor physical condition who are not suitable for blood draw\n* Patients who cannot provide informed consent or refuse blood draw\n\nExclusion Criteria for Benign Diseases Arm Participants:\n\n* History of malignancies\n* Current malignancies or precancerous lesions",{"count":381,"type":22},200,"The purpose of this study is to construct an auxiliary diagnostic model for breast cancer by methylation markers. The study will collect blood and tissue samples from participants with breast cancer and benign disease for whole-genome methylation sequencing. It will screen methylation markers and develop a methylation auxiliary diagnosis model to distinguish between breast cancer and non-cancer.",[29],"2025-03-12",{"date":386,"type":34},"2025-03-14",{"date":388,"type":22},"2025-03-15",{"date":390,"type":22},"2026-08-31",{"name":392,"class":393},"Geneplus-Beijing Co. Ltd.","INDUSTRY"]